GRTS - Gritstone Oncology Inc Stock Price, Fair Value and News

0.74USD-0.10 (-11.90%)Market Closed

Market Summary

USD0.74-0.10

Market Closed

-11.90%

GRTS Stock Price

View Fullscreen

GRTS RSI Chart

GRTS Valuation

Market Cap

82.4M

Price/Earnings (Trailing)

-0.59

Price/Sales (Trailing)

5.04

Price/Free Cashflow

-0.65

GRTS Price/Sales (Trailing)

GRTS Profitability

Return on Equity

-267.12%

Return on Assets

-77.91%

Free Cashflow Yield

-153.17%

GRTS Fundamentals

GRTS Revenue

Revenue (TTM)

16.3M

Rev. Growth (Yr)

143.59%

Rev. Growth (Qtr)

563.39%

GRTS Earnings

Earnings (TTM)

-138.5M

Earnings Growth (Yr)

1.48%

Earnings Growth (Qtr)

19.79%

Breaking Down GRTS Revenue

Last 7 days

-13.4%

Last 30 days

-64.4%

Last 90 days

-70.2%

Trailing 12 Months

-71.9%

How does GRTS drawdown profile look like?

GRTS Financial Health

Current Ratio

3.2

Debt/Equity

0.77

Debt/Cashflow

-3.03

GRTS Investor Care

Shares Dilution (1Y)

11.87%

Diluted EPS (TTM)

-1.2

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	15.2M	11.7M	10.2M	16.3M
2022	15.7M	18.3M	18.7M	19.9M
2021	42.5M	44.8M	46.5M	48.2M
2020	4.3M	3.6M	3.6M	4.0M
2019	2.4M	3.7M	4.6M	4.4M
2018	0	0	0	1.2M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Gritstone Oncology Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 01, 2024	cho james	acquired	-	-	18,000	svp, chief accounting officer
Feb 01, 2024	allen andrew r	acquired	-	-	105,000	president and ceo
Feb 01, 2024	hawryluk matthew	acquired	-	-	35,000	evp, chief business officer
Feb 01, 2024	jooss karin	acquired	-	-	40,000	see remarks
Feb 01, 2024	economides vassiliki	acquired	-	-	35,000	evp, chief financial officer
Feb 01, 2024	jones erin	acquired	-	-	40,000	evp, chief operating officer
May 23, 2023	economides vassiliki	bought	22,828	1.9024	12,000	see remarks
Feb 02, 2023	economides vassiliki	acquired	-	-	179,058	see remarks
Feb 02, 2023	jones erin	acquired	-	-	252,845	see remarks
Feb 02, 2023	allen andrew r	acquired	-	-	738,550	president and ceo

Which funds bought or sold GRTS recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Mar 22, 2024	PNC FINANCIAL SERVICES GROUP, INC.	reduced	-99.43	-17,084	116	-%
Mar 11, 2024	VANGUARD GROUP INC	added	8.82	2,029,100	9,009,240	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	added	47.71	240,166	559,588	-%
Feb 28, 2024	AMERICAN INTERNATIONAL GROUP, INC.	reduced	-0.4	13,658	88,997	-%
Feb 16, 2024	PRICE T ROWE ASSOCIATES INC /MD/	added	3.67	32,000	171,000	-%
Feb 15, 2024	JANE STREET GROUP, LLC	new	-	410,004	410,004	-%
Feb 15, 2024	WEXFORD CAPITAL LP	new	-	25,826	25,826	0.01%
Feb 15, 2024	Legal & General Group Plc	reduced	-15.69	-43.00	14,521	-%
Feb 15, 2024	Farther Finance Advisors, LLC	new	-	49.00	49.00	-%
Feb 15, 2024	BARCLAYS PLC	added	285	227,000	289,000	-%

Are Funds Buying or Selling GRTS?

Are funds buying GRTS calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own GRTS

No. of Funds

Unveiling Gritstone Oncology Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	point72 asset management, l.p.	4.2%	3,974,867	SC 13G/A
Feb 14, 2024	redmile group, llc	9.9%	10,135,388	SC 13G/A
Feb 13, 2024	frazier life sciences public fund, l.p.	0.0%	0	SC 13G/A
Feb 08, 2024	morgan stanley	5.8%	5,519,102	SC 13G
Jan 29, 2024	blackrock inc.	6.2%	5,868,353	SC 13G
Feb 14, 2023	frazier life sciences public fund, l.p.	5.0%	4,131,470	SC 13G/A
Feb 14, 2023	avidity partners management lp	3.3%	2,859,971	SC 13G/A
Feb 14, 2023	point72 asset management, l.p.	9.2%	7,679,867	SC 13G/A
Feb 14, 2023	redmile group, llc	9.9%	8,483,322	SC 13G/A
Feb 10, 2023	ecor1 capital, llc	0%	0	SC 13G/A

Recent SEC filings of Gritstone Oncology Inc

View All Filings

Date Filed	Form Type	Document
Apr 02, 2024	424B5	Prospectus Filed
Apr 02, 2024	8-K	Current Report
Apr 01, 2024	424B5	Prospectus Filed
Apr 01, 2024	8-K	Current Report
Mar 05, 2024	10-K	Annual Report
Mar 05, 2024	8-K	Current Report
Mar 05, 2024	S-8	Employee Benefits Plan
Feb 29, 2024	8-K	Current Report
Feb 14, 2024	SC 13G/A	Major Ownership Report
Feb 14, 2024	SC 13G/A	Major Ownership Report

Peers (Alternatives to Gritstone Oncology Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	39.7B	6.8B	-1.24%	-34.47%	-8.42	5.79	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.7B	1.8B	0.05%	-28.38%	-42.48	10.23	76.23%	61.08%
BMRN	17.4B	2.4B	8.82%	-6.19%	103.82	7.19	15.42%	18.43%
INCY	12.1B	3.7B	-8.57%	-28.49%	20.24	3.27	8.87%	75.42%
MID-CAP
APLS	6.2B	396.6M	-9.73%	-34.59%	-11.81	15.75	425.83%	18.94%
BBIO	4.7B	-	-4.69%	71.46%	-7.22	60.35	54.84%	-34.79%
AXSM	3.3B	270.6M	-0.99%	6.40%	-13.69	12.11	440.80%	-27.84%
ARWR	3.1B	240.7M	-13.54%	-18.95%	-10.31	12.71	-1.03%	-92.09%
ACAD	2.8B	726.4M	-12.42%	-7.51%	-46.08	3.89	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-8.48%	-15.36%	25.42	4.56	85.90%	-14.05%
NVAX	576.6M	983.7M	-18.48%	-55.04%	-1.06	0.59	-50.36%	17.16%
CRBP	448.6M	881.7K	-13.30%	407.71%	-10.06	466.16	-77.61%	-5.33%
INO	256.8M	4.9M	-1.96%	-2.22%	-1.9	52.78	-54.97%	51.72%
IBIO	6.7M	2.1M	77.59%	88.99%	-0.25	2.14	-13.45%	66.37%

Gritstone Oncology Inc News

Latest updates

Gritstone Oncology Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	563.4%	10,382	1,565	1,955	2,443	4,262	3,021	5,471	7,191	3,064	2,614	2,843	39,693	1,348	939	488	1,262	884	984	1,150	1,347	1,091
Operating Expenses	1.7%	40,854	40,169	37,683	37,259	36,182	32,898	35,139	36,154	32,848	30,769	28,009	31,797	28,496	27,081	26,545	27,933	29,197	29,468	23,364	20,276	19,119
S&GA Expenses	-100.0%	-	7,406	6,716	6,745	6,761	6,462	7,792	7,955	6,682	6,373	5,937	6,941	5,660	5,031	5,255	5,465	5,615	4,582	4,835	4,377	3,866
R&D Expenses	0.5%	32,938	32,763	30,967	30,514	43,520	26,436	27,347	-	26,166	24,396	22,072	24,856	22,836	22,050	21,290	22,468	23,582	24,886	18,529	15,899	15,253
Interest Expenses	22.8%	1,217	991	985	844	672	551	-	24.00	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	19.8%	-30,828	-38,434	-35,256	-33,982	-31,290	-29,966	-29,515	-28,916	-29,769	-28,118	-25,118	7,923	-27,167	-26,073	-25,868	-26,206	-27,704	-27,548	-21,172	-18,009	-17,338
Net Income Margin	37.7%	-8.47*	-13.59*	-11.17*	-8.21*	-6.00*	-6.30*	-6.34*	-7.12*	-1.56*	-1.56*	-1.57*	-1.68*	-	-	-	-	-	-	-	-	-
Free Cashflow	38.7%	-19,691	-32,140	-32,674	-41,667	-31,829	-26,936	-27,790	-35,263	-25,108	-16,373	-24,370	9,710	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-5.0%	178	187	223	210	241	205	214	243	278	271	224	247	222	123	146	163	184	209	228	175	190
Current Assets	-3.7%	87.00	91.00	122	155	183	153	162	193	221	218	177	203	175	74.00	94.00	112	131	155	185	135	158
Cash Equivalents	138.9%	71.00	30.00	41.00	47.00	55.00	77.00	80.00	84.00	111	148	65.00	109	171	59.00	64.00	56.00	58.00	118	109	36.00	53.00
Net PPE	-8.8%	17.00	19.00	20.00	20.00	21.00	22.00	23.00	22.00	22.00	21.00	22.00	22.00	22.00	23.00	25.00	26.00	27.00	24.00	19.00	16.00	29.00
Liabilities	11.2%	126	113	113	69.00	70.00	68.00	51.00	54.00	62.00	63.00	45.00	48.00	55.00	51.00	49.00	48.00	50.00	52.00	46.00	43.00	40.00
Current Liabilities	16.9%	27.00	23.00	22.00	25.00	35.00	32.00	32.00	34.00	40.00	36.00	21.00	22.00	27.00	22.00	19.00	18.00	20.00	23.00	18.00	14.00	15.00
Long Term Debt	34.4%	40.00	30.00	30.00	30.00	19.00	19.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
LT Debt, Non Current	-100.0%	-	30.00	30.00	30.00	19.00	19.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Shareholder's Equity	-29.9%	52.00	74.00	110	141	171	137	163	189	216	208	179	199	167	72.00	96.00	115	134	156	182	132	149
Retained Earnings	-4.9%	-659	-628	-590	-555	-521	-489	-459	-430	-401	-371	-343	-318	-326	-299	-273	-247	-220	-193	-165	-144	-126
Additional Paid-In Capital	1.2%	711	703	700	696	692	627	624	620	618	580	522	518	493	371	369	363	355	350	348	277	276
Shares Outstanding	4.8%	98.00	93.00	91.00	88.00	87.00	86.00	86.00	86.00	69.00	78.00	76.00	76.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	174	-	-	-	172	-	-	-	419	-	-	-	199	-	-	-	277	-	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	37.2%	-19,500	-31,047	-30,953	-40,100	-30,346	-25,812	-26,337	-33,451	-23,778	-14,900	-22,700	10,700	-25,200	-20,200	-20,723	-22,977	-22,452	-25,059	-18,373	-19,127	-13,034
Share Based Compensation	-4.8%	2,823	2,964	2,940	2,891	3,008	3,064	3,354	3,131	2,799	2,819	2,733	2,201	1,695	1,839	1,957	1,619	1,443	1,532	1,317	1,007	1,321
Cashflow From Investing	109.5%	38,295	18,281	24,592	21,173	-46,152	3,075	22,479	7,634	-46,626	41,160	-23,487	-89,600	11,618	15,732	23,825	14,774	-41,349	33,983	21,777	1,430	-91,461
Cashflow From Financing	6053.4%	15,717	-264	1,017	8,647	64,365	19,340	310	-917	32,877	56,743	1,745	17,395	125,432	37.00	4,677	5,655	4,267	252	69,790	86.00	90,704

GRTS Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Revenue recognized grant revenue	$ 16,344	$ 19,945	$ 48,214
Operating expenses:
Research and development	127,182	111,403	97,490
General and administrative	28,783	28,970	25,933
Total operating expenses	155,965	140,373	123,423
Loss from operations	(139,621)	(120,428)	(75,209)
Interest income	5,199	1,976	164
Interest expense	(4,036)	(1,235)	(37)
Other expense	(32)	0	0
Net loss	(138,490)	(119,687)	(75,082)
Other comprehensive loss:
Unrealized loss on marketable securities	83	(7)	(73)
Comprehensive loss	$ (138,407)	$ (119,694)	$ (75,155)
Net loss per share, basic	$ (1.2)	$ (1.32)	$ (0.95)
Net loss per share, diluted	$ (1.2)	$ (1.32)	$ (0.95)
Weighted-average number of shares used in computing net loss per share, basic	115,527,546	90,918,333	78,885,186
Weighted-average number of shares used in computing net loss per share, diluted	115,527,546	90,918,333	78,885,186
Collaboration and license revenues [Member]
Revenue recognized grant revenue	$ 1,331	$ 9,269	$ 46,717
Grant revenues [Member]
Revenue recognized grant revenue	$ 15,013	$ 10,676	$ 1,497

GRTS Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 62,986	$ 55,498
Marketable securities	16,288	116,389
Restricted cash	2,299	3,977
Prepaid expenses and other current assets	5,862	7,014
Total current assets	87,435	182,878
Long-term restricted cash	5,290	5,290
Property and equipment, net	17,281	21,335
Lease right-of-use assets	66,839	17,481
Deposits and other long-term assets	924	9,739
Long-term marketable securities	0	4,031
Total assets	177,769	240,754
Current liabilities:
Accounts payable	3,819	8,694
Accrued compensation	9,357	8,215
Accrued liabilities	1,213	4,124
Accrued research and development expenses	3,696	3,343
Lease liabilities, current portion	6,904	5,294
Deferred revenue, current portion	2,350	5,131
Total current liabilities	27,339	34,801
Other liabilities, noncurrent	709	150
Lease liabilities, net of current portion	57,727	15,673
Debt, noncurrent	40,144	19,349
Total liabilities	125,919	69,973
Commitments and contingencies (Notes 6, 7 and 8)
Stockholders’ equity:
Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding at December 31, 2023 and 2022	0	0
Common stock, $0.0001 par value; 300,000,000 shares authorized at December 31, 2023 and 2022; 97,585,415 and 86,894,901 shares issued and outstanding at December 31, 2023 and 2022, respectively	22	22
Additional paid-in capital	711,386	691,910
Accumulated other comprehensive gain (loss)	3	(80)
Accumulated deficit	(659,561)	(521,071)
Total stockholders’ equity	51,850	170,781
Total liabilities and stockholders’ equity	$ 177,769	$ 240,754

About Gritstone Oncology Inc

Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases. Its primary product candidate is GRANITE, a neoantigen-based immunotherapy, which is in Phase 2/3 clinical trials for the treatment of solid tumors, including microsatellite stable colorectal cancers. The company is also developing SLATE, an off-the-shelf immunotherapy candidate, which is in Phase 2 clinical trials for the treatment of metastatic solid tumors. In addition, it develops CORAL, a SARS-CoV-2 vaccine platform designed to deliver spike and additional SARS-CoV-2 T cell epitopes for protection and broader immunity against SARS-CoV-2 variants; and a therapeutic vaccine candidate designed to treat and cure human immunodeficiency virus (HIV) infection. Gritstone bio, Inc. has a strategic collaboration with bluebird bio, Inc.; collaboration agreement with Gilead Sciences, Inc.; and license agreement with Genevant Sciences GmbH. The company was formerly known as Gritstone Oncology, Inc. and changed its name to Gritstone bio, Inc. in May 2021. Gritstone bio, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.

CEO	Dr. Andrew R. Allen BCh, BM, M.D., MA, MRCP, Ph.D.
WEBSITE	https://gritstonebio.com
INDUSTRY	Biotechnology
EMPLOYEES	233

Gritstone Oncology Inc Frequently Asked Questions

What is the ticker symbol for Gritstone Oncology Inc? What does GRTS stand for in stocks?

GRTS is the stock ticker symbol of Gritstone Oncology Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Gritstone Oncology Inc (GRTS)?

As of Fri Apr 12 2024, market cap of Gritstone Oncology Inc is 82.38 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of GRTS stock?

You can check GRTS's fair value in chart for subscribers.

What is the fair value of GRTS stock?

You can check GRTS's fair value in chart for subscribers. The fair value of Gritstone Oncology Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Gritstone Oncology Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for GRTS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Gritstone Oncology Inc a good stock to buy?

The fair value guage provides a quick view whether GRTS is over valued or under valued. Whether Gritstone Oncology Inc is cheap or expensive depends on the assumptions which impact Gritstone Oncology Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for GRTS.

What is Gritstone Oncology Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 12 2024, GRTS's PE ratio (Price to Earnings) is -0.59 and Price to Sales (PS) ratio is 5.04. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. GRTS PE ratio will change depending on the future growth rate expectations of investors.